All articles tagged with #biotechnology
Tech billionaires and biohackers are backing the Enhanced Games, a Las Vegas spectacle intended to normalize longevity and performance-enhancing drugs. The piece follows Christian Angermayer’s self-experimentation and argues the venture aims to turn doping into a billion-dollar business, despite widespread ethical and safety concerns about such a platform.
Scientists have shown that DNA polymerases can generate long, patterned DNA without a template, producing tens of thousands of units by adjusting reaction conditions such as temperature and building-block availability. The output forms identifiable repeating patterns rather than random strings, suggesting a tunable pathway for long DNA synthesis with potential biotech applications, though researchers caution about error control and the uncertain behavior in living systems.
Regenxbio announced its experimental Duchenne muscular dystrophy gene therapy produced sufficient levels of a miniaturized muscle protein in a clinical trial, paving the way for an FDA submission and aiming to improve on Sarepta’s Elevidys in both efficacy and safety, amid ongoing safety concerns surrounding the competitor.
After a failed stem-cell transplant, a 13-month-old boy received a novel gene-therapy treatment and initially made progress, but a routine scan later revealed a golf-ball-sized brain tumor; scientists say the tumor may be linked to the gene-therapy viruses, highlighting the need to weigh life-saving benefits against rare but serious risks in such approaches.
AI-based biology tools can design proteins, toxins, and even viruses, prompting debate over safeguards: some researchers say current risk is limited and production requires expertise, while others warn AI could empower bad actors. The discussion spans whether to restrict biological AI or to improve detection and screening of DNA orders; experiments show screening can be bypassed but improvements reduce risk. Policy efforts such as DNA-synthesis screening, guard rails, and international guidelines are evolving as scientists push for responsible AI practices, acknowledging the threat is serious but not inevitable.
Corteva announced that its advanced seed and genetics business will spin off as Vylor, Inc., targeting a Q4 2026 separation. Backed by thousands of germplasm and biotech patents, Vylor will push a pipeline featuring proprietary hybrid wheat, gene editing, multi-disease‑resistant corn, and next‑generation biofuels, and plans to expand into new row crops while leveraging Corteva’s global network and leading market shares; the brand honors its heritage and signals a focus on science to feed and fuel the world.
A futurist argues we could reach longevity escape velocity by 2029—lifespan could grow faster than aging through rapid biotech and AI progress—yet realizing this for individuals remains uncertain. The piece also cautions about practical limits, uneven global access to advanced medicine, and the persistent risks of disease and accidents that could prevent immortality from becoming a reality.
STAT memorializes J. Craig Venter, detailing how his audacious push to map and rewrite genomes—racing the Human Genome Project with Celera, sequencing microbes with Ham Smith, and pioneering synthetic biology—transformed biomedical science, while also provoking debate over patents, profit, and access in the biotech era.
Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion in cash (upfront $3.25B) to gain Kelonia's in vivo gene delivery platform and KLN-1010, an in vivo anti-BCMA CAR-T therapy for multiple myeloma in Phase 1, with the aim of simplifying manufacturing and broadening access versus ex vivo CAR-T; the deal is expected to close in the second half of 2026, subject to regulatory approvals and milestone-driven payments.
UCLA researchers report MethylScan, a simple, affordable test that analyzes DNA methylation in circulating cell-free DNA to detect multiple cancers and liver diseases, and to indicate tissue of origin and organ health. In 1,061 samples, it achieved about 98% specificity, ~63% cancer detection across stages (~55% for early-stage) and ~80% detection of liver cancers in high‑risk groups, with a sequencing depth of ~300× costing under $20 per test as costs fall. By reducing background DNA, it functions as a system-wide health monitor, though larger prospective studies are needed to confirm real-world effectiveness.
Fraunhofer researchers identified a compound—guanidinoethylbenzylamino imidazopyridine acetate—that blocks growth of periodontitis-causing bacteria like Porphyromonas gingivalis without killing beneficial oral microbes, enabling PerioTrap to develop a toothpaste that helps prevent gum disease while preserving the oral microbiome; the project followed GLP standards and also produced a post-cleaning gel, with future products (mouthwash, veterinary uses) in development.
The FDA has once more rejected Replimune’s engineered virus therapy for advanced melanoma, a decision that underscores the ongoing debate over tightening agency standards amid leadership changes; the treatment is designed to boost the immune system’s attack on skin cancer, but regulators say the data remain insufficient.
Five years after a lupus patient achieved lasting remission with CAR-T therapy, the case has stirred broad pharma interest and spurred ongoing research into CAR-T for autoimmune diseases, offering renewed hope while highlighting challenges ahead.
Researchers engineered E. coli to convert PET-derived terephthalic acid into levodopa, a Parkinson’s drug, via a two-step metabolic pathway in a lab proof-of-concept using sequential bacterial strains; not yet scalable, but it demonstrates a potential plastic-to-pharma recycling route and eco-friendly drug production, building on earlier work turning PET into other medicines. Published in Nature Sustainability with EPSRC funding.
Scientists are turning DNA into programmable nanomachines that can move, sense, and deliver therapies, using DNA origami and strand displacement to create DNA robots that could autonomously seek out cancer cells or viruses in the bloodstream; while early demonstrations show targeted drug delivery and precise nanoparticle placement, major challenges remain in controlling motion, ensuring stability in the body, and scaling production for real-world medical use.